“…Indeed, of the nanomedicine drugs approved by the Federal Drug Administration (FDA), lipid-based systems constitute the vast majority and are the leading material in future drug development systems. 14,15 In addition, lipids exist in numerous complex structures within the ECM including exosomes and several other lipidbased extracellular vesicles, 16 which have been implicated in ECM modulation within several physiological and pathological contexts. 17 To prevent protein adsorption onto nanoparticles, poly(ethylene glycol) (PEG) has been incorporated onto the surfaces of nanoparticles via the inclusion of a lipid that is covalently linked to PEG, effectively "cloaking" the particle to evade protein interactions, thus prolonging their circulation lifetime.…”